The field of biotechnology has come a long way and has made significant strides in developing new treatments for various ailments. One company that is at the forefront of this innovative industry is Defence Therapeutics Inc. Recently, the company has made a major breakthrough with their new vaccine platform called ACCUM(TM)-mRNA. The platform is the first of its kind, and the company has successfully engineered it to become a viable option for creating new kinds of vaccines. Their first target is creating an in vivo ACCUM(TM)-mRNA cancer vaccine program. This breakthrough has potential implications for saving countless lives and is the first step in opening horizons in the world of virology.
Defence Therapeutics Inc., a Canadian biopharmaceutical company specializing in the development of immune-oncology vaccines and drug delivery technologies, has made a breakthrough in cancer vaccines. The company successfully established a strategy that conjugates mRNA molecules to AccumTM, creating a new vaccine platform for in vivo cancer vaccines. As expected, the potency of the modified product is enhanced, making it capable of producing a powerful immune response, unlike “naked” mRNA administered as vaccines in immunocompetent mice. Administration of a “naked” mRNA molecule encoding for the ovalbumin protein resulted in weak to moderate antibody titers in mice.
Defence Therapeutics Inc. has completed its AccumTM-mRNA vaccine engineering and synthesis, and the final product is stable, and an SOP has been finalized to enable the same method’s application to any chosen mRNA molecule. The company has begun in vivo studies to compare the immunogenicity of the vaccine. The potency of the AccumTM-mRNA vaccine will first be tested on cancer solid T-cell lymphoma and subsequently on additional cancer solid tumors. Defence plans to develop its own AccumTM-linked mRNA vaccines for different cancer indications while establishing partnerships with companies currently testing/developing mRNA vaccines for both immune-oncology and infectious disease indications.
The success of this breakthrough technology signals that mRNA vaccination holds great promise over the use of other vaccination modalities. The mRNA therapeutics market size is expected to surpass about USD 128.14 billion by 2030 and growing at a CAGR of 13.03% from 2022 to 2030, according to Precedence Research.
Defence Therapeutics has developed a proprietary platform, the ACCUMTM technology, which enables the precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases. The success of the company’s AccumTM-mRNA vaccine engineering and synthesis is expected to lead to ground-breaking alternative cancer treatments.
Despite representing a promising technology, mRNA vaccines have not reached their potential, but Defence Therapeutics has unlocked this potential through the use of AccumTM technology. The company’s breakthrough offers a new vaccine platform for in vivo cancer vaccines, and the potency of the vaccine is expected to be massively boosted, resulting in a powerful immune response.
In conclusion, Defence Therapeutics Inc. has achieved a major breakthrough in the field of mRNA vaccine development with the successful engineering of the ACCUM(TM) platform. This exciting technology has the potential to revolutionize vaccine design and delivery, paving the way for new treatments and cures for a range of diseases, including cancer. With the in vivo ACCUM(TM)-mRNA cancer vaccine program now underway, the future looks bright for Defence Therapeutics Inc. and the patients who stand to benefit from their groundbreaking research. Stay tuned for further developments from this innovative and dynamic company.
